Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Mazzotta F, Lo Caputo S, Pierotti P, Carosi G; GenPheRex PhenGen Study Groups of the MASTER Cohort. Torti C, et al. Among authors: angarano g. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1104-7. doi: 10.1097/00126334-200408150-00016. J Acquir Immune Defic Syndr. 2004. PMID: 15247566 Clinical Trial. No abstract available.
Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).
Saracino A, Monno L, Locaputo S, Torti C, Scudeller L, Ladisa N, Antinori A, Sighinolfi L, Chirianni A, Mazzotta F, Carosi G, Angarano G. Saracino A, et al. Among authors: angarano g. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1587-98. doi: 10.1097/00126334-200412150-00011. J Acquir Immune Defic Syndr. 2004. PMID: 15577415 Clinical Trial.
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Lo Caputo S, Tirelli V, Mazzotta F, Carosi G; MASTER Cohort GenPheRex Study Group; MASTER Cohort PhenGen Study Group. Torti C, et al. Among authors: angarano g. J Med Virol. 2004 Sep;74(1):29-33. doi: 10.1002/jmv.20142. J Med Virol. 2004. PMID: 15258965
Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure.
Balotta C, Violin M, Monno L, Bagnarelli P, Riva C, Facchi G, Berlusconi A, Lippi M, Rusconi S, Clementi M, Galli M, Angarano G, Moroni M. Balotta C, et al. Among authors: angarano g. J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):232-40. doi: 10.1097/00126334-200007010-00007. J Acquir Immune Defic Syndr. 2000. PMID: 10969347
Are the proposed env mutations actually associated with resistance to maraviroc?
Saracino A, Monno L, Brindicci G, Trillo G, Altamura M, Punzi G, Lagioia A, Angarano G. Saracino A, et al. Among authors: angarano g. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):550-2. doi: 10.1097/QAI.0b013e3181ba46a6. J Acquir Immune Defic Syndr. 2010. PMID: 20220379 No abstract available.
Clinical aspects of antiretroviral resistance.
Angarano G, Monno L. Angarano G, et al. J Biol Regul Homeost Agents. 1998;12(1-2 Suppl):28-31. J Biol Regul Homeost Agents. 1998. PMID: 9689576 No abstract available.
408 results